INTRODUCTION
Since the implementation of PSA annual screening, the number of prostate cancer (PCa) cases diagnosed each year has increased significantly. 1 PCa now is the most and second most detected cancer in men in developed countries and worldwide, respectively. 2 Early detection saves lives of patients harboring lethal PCa; however, PSA testing has also led to a significant increase in overtreatment of patients with slow-progressing or clinically insignificant tumors. Although the critical role of Gleason score and the incidence of PCa recurrent potential has been recognized, 3, 4 current pathology is often unable to distinguish latent from aggressive tumors and it was estimated that radical procedures on approximately 73 patients would be necessary to avert one death of PCa. 5 Thus, in the US alone, with more than 420 prostatectomies performed each day, the number of patients needlessly affected by therapeutic morbidities is considerable. 6, 7 To improve clinical ability in assessing PCa grade, stage and malignant potential, tumor biology studies have correlated these clinical parameters with various molecular biomarkers 8 --12 and have concentrated on discovering possible inhibitory factors that may account for the existence of a large population of latent PCa. As a very active research arena, the relationships between oncogenic mutations of prostate epithelial cells and the levels of zinc concentrations, zinc transporter protein expression, and the metabolic intensity of citrate in these cells have been proposed, 13, 14 and widely tested, 15 --17 including the proposals of imaging. 18, 19 Briefly, it is known that zinc levels in the benign tissue of prostate peripheral zone are the highest among any soft tissue in the human body; these levels do not change in BPH, but are diminished in PCa. 13, 14, 20 The high levels of zinc are believed to be the result of zinc transporter proteins, including those from the zinc transporters family, that are responsible for prostate epithelial cell zinc uptake, and the ZnT family, responsible for zinc sequester and release. 17 Particularly, it was found that hZip1 was markedly downregulated in PIN and PCa when compared with BPH and normal prostate epithelia. 13 Zinc functions as an inhibitor of the enzyme m-aconitase, which reduces the amount of citrate oxidized in the Krebs cycle, resulting in a high level of citrate produced and secreted by the prostate glandular epithelia. 13, 21, 22 Thus, reduced zinc levels in PCa engender a decrease in secreted citrate levels as citrate enters the Krebs cycle. This phenomenon has been reported by numerous studies including in vivo magnetic resonance spectroscopy (MRS) imaging and ex vivo PCa cells, tissues and prostatic fluid. 13,23 --25 In the current study, we test the relationship between the levels of secreted citrate in the glandular epithelia of PCa patients and the progression of PCa. However, assessing PCa progression in patients is challenging owing to the inability of current radiological tests in detecting prostate lesions, quantifying tumor size and evaluating cancer malignant potential in vivo, whereas interventions of prostatectomy or radiotherapy are the available therapeutic options for patients with biopsy-proven PCa. To circumvent the clinical impasse, we selected a group of patients who had multiple pre-interventional elevated PSA readings but negative biopsies over time, until the eventual cancer-positive biopsy that led to prostatectomy. We obtained tissue specimens from the prostate peripheral zone in each patient. Patient pre-surgical PSA and percent-free PSA (FreePSA%) readings, as well as the weight of prostates, were recorded and used to calculate PSA velocities (V PSA ) and PSA densities (D PSA ). These parameters (V PSA , D PSA , and FreePSA%) were used as surrogate markers of PCa growth rates.
We measured citrate concentrations in intact tissue samples with high-resolution magic angle spinning proton magnetic resonance spectroscopy (HRMAS 1 HMRS), 26 followed by quantitative histopathology of the same specimens. Using these data, we evaluated correlations between citrate concentrations and V PSA , D PSA , and FreePSA%.
MATERIALS AND METHODS

Patient population and tissue samples
The study was approved by the institutional review board at Massachusetts General Hospital. From a PCa tumor bank database of about 1050 patients that had undergone radical prostatectomy between January 2006 and May 2009, we identified 18 patients with 3 to 10 consecutive observations of PSA elevations measured at intervals of at least six months and negative biopsies before final biopsy-proven PCa. All patients had radical prostatectomies with pre-surgical PSA values less than 20 ng/ml, and linear regression analysis of their PSA values produced V PSA of high linearity (r 2 40.85) and statistical significance (Po0.05). No prostatitis was reported with these patients, and only one patient presented BPH, discovered at histological evaluation after prostatectomy. The average body mass index for these patients was 29.4 ( ± 3.9) and eight of the patients were identified as being white, whereas the races of the remaining patients are unknown. Frozen prostate tissue specimens from these 18 cases were obtained from the PCa tumor bank that was established in 2001 for the purpose of collecting prostate tissue for research including extraction of RNA, DNA and proteins, human molecular genetics studies and the establishment of specific tumor cell lines.
Resected specimens are sent to the frozen section lab, where they are dissected for diagnosis by the pathology staff, and excess tissue is collected by the technicians and snap-frozen for transportation and storage in liquid nitrogen. Using these specimens, we conducted 27 individual measurements of tissue spectroscopy and quantitative pathology for these 18 patients (Table 1) . We also recorded patient FreePSA% when available and the weight of prostates measured after prostatectomies. The PSA densities, D PSA , were calculated using patient pre-surgical PSA values divided by the weights of the removed prostates.
MRS
Spectroscopy procedures have been previously published. 27 Briefly, frozen tissue samples (B10 mg) and 1.0 ml of D 2 O were loaded into 4 mm Zirconia rotors with spherical inserts (B12 ml) and introduced into the HRMAS probe, pre-cooled to 4 1C. Spectroscopy measurements were carried out on a Bruker AVANCE spectrometer (Bruker BioSpin, Billerica, Massachusetts, USA), operating at 600 MHz (14.1T). Spectra were acquired with the spectrometer frequency set exactly on the water resonance. Two types of spectra were acquired for this analysis: (1) single 901 excitation pulse to measure total resonance intensity, including tissue water and (2) continuous-wave water presaturation rotor-synchronized CPMG sequence with a 20-ms delay after the 901 excitation pulse. These spectra were acquired using slow spinning rates of 600 and 700 Hz and post-spectral edited with Min(A, B) scheme to eliminate spinning side-band effects. 27 Spectroscopic data were processed using Nuts software (Acorn NMR, Livermore, CA, USA). All free induction decays were subjected to 0.5 Hz apodization before Fourier transformation, baseline correction, and phase adjustment. Min(A, B) was applied to the data in the frequency domain after all individual spectra had been processed. The resonance intensities reported here represent integrals of curve-fittings with Lorentzian --Gaussian line-shapes, normalized by water intensity measured for each sample. Citrate concentrations were determined by resonances at 2.51, 2.54, 2.67, and 2.70 ppm.
Quantitative histopathology
Following spectroscopy, samples were fixed in 10% formalin, embedded in paraffin, cut into 5-micron sections at 100-micron intervals throughout the entire sample, and stained with hematoxylin and eosin. A pathologist with no knowledge of the spectroscopic results visually estimated the area% representing cancer cells, normal epithelial cells, and stroma in each crosssection to the nearest 5%. The volume% of these features was calculated from the corresponding area% of each pathological feature on the different cross-sections. 
RESULTS
Quantification of citrate concentrations in prostate tissue
The resonances of citrate can be measured from intact prostate tissue spectra, as shown in Figure 1 . Plots (a, b and c) are taken from a spectrum measured with a single 901 excitation pulse. From this spectrum, the resonance intensities of tissue water (including the center band and visible spinning side-bands) and cellular metabolites are presented with the total spectral intensity proportional to the total tissue mass. Plot (d) is the composite spectrum obtained using the Min(A, B) scheme, 27 where waterpresaturated spectra A and B were measured with 600 and 700 Hz HRMAS rates, respectively. Citrate and other metabolites are clearly quantifiable from the spectrum (d).
Because spectra (a) and (d) were measured under different experimental conditions, the intensity of citrate measured from (d) cannot be normalized by the total spectral intensity (from 0 to 10 ppm) of (a) directly. The prominent appearance of lactate doublet resonances at 1.33 ppm in both spectra (see b, c and d) can be used as a suitable common factor to convert citrate intensity measured in the water-presaturated spectrum (d) to the estimated citrate concentration based on the entire measurable tissue spectral intensity including tissue water and metabolites presented in (a). Hence, the concentration of citrate is assessed by the following formula:
where, I Cit and I Lac are resonance intensities of citrate and lactate, respectively, measured from spectrum (d), while I Lac/H2O and I H2O represent lactate and total spectral intensity (0 --10 ppm), respectively, measured from spectrum (a). The above equation also recognizes that six and two protons in citrate and water, respectively, contributed to their resonance peaks, and that soft tissue contains about 80% water.
Secretion of citrate in histo-benign epithelia
The secretion of citrate in the benign prostate epithelia has been shown in literature, including our previously reported MRS results. 28 With the current 18 cases and 27 individual MRS and histology measurements, more detailed secretion patterns are observed while the overall correlation between the measured citrate concentrations and the volume percentages of histobenign epithelia is maintained. In Figure 2 , we arranged data of citrate vs histo-benign epithelia in three groups, with samples from the low V PSA group presented in small dots (n ¼ 12), median V PSA group in median dots (n ¼ 9), and fast V PSA group in large open circles (n ¼ 6). This data arrangement reveals that, although a linear correlation between citrate and histo-benign epithelia is measurable for the entire data set with statistical significance (the dashed line, P ¼ 0.023, r 2 ¼ 0.19), the scattering is mostly caused by the data dispersion of the fast V PSA group. Thus evaluating the slow and median groups revealed much stronger linearity and statistical significance (the solid line, Po0.0001, r 2 ¼ 0.56) of a relationship between citrate concentrations and volume percentages of histo-benign epithelia. Of note, no correlation was observed when citrate concentrations were evaluated against volume percentages of cancer and stroma components in these tissue samples.
Citrate concentrations in histo-benign epithelia and PCa growth rates Transformation and progression of PCa can result in alterations of prostate metabolism that may be transparent to histopathology. By considering the relationships between the Zn 2 þ Cit complex and prostate tumor growth from cell-line studies, 22 the observation of citrate correlations with benign prostate epithelia in PCa, 28 and the deviation from this relationship in fast-growing tumors represented by high V PSA group above, we evaluated the relationship between concentrations of citrate in unit histologically benign-prostate-epithelia (citrate/epithelia, or Cit/Epi) and the PCa growth rate, as indicated by V PSA , D PSA , and FreePSA%. The results presented by cases, where multiple measurements Figure 1 . Prostate tissue HRMAS proton magnetic resonance spectroscopy. The illustrated spectra were measured from a 7.7-mg tissue sample of the peripheral zone of Case #1989 (Table 1) . Histological quantification of this tissue specimen after spectroscopy analysis revealed the following features: cancer 5.9%, benign epithelia 25.7%, and stroma 68.4%. from the same case were averaged, are shown in Figure 3 . Among the 18 cases studied, histopathological evaluations after spectroscopy analysis revealed that one of them did not contain any histo-benign epithelia within the analyzed samples. Therefore, no valid Cit/Epi values can be assessed for this case. Data from the remaining 17 cases show statistically significant correlations between the tumor growth rate revealed by V PSA , D PSA , and FreePSA%, and the measurable amount of citrate in unit cells. In contrast, there was no observable relationship between citrate concentrations and the patients' measured Gleason scores at time of surgery.
DISCUSSION
Encouraged by cell-line studies showing the correlation between expression levels of prostatic intraepithelial zinc transporters and cell growth rate, as well as the knowledge about the zinc --citrate complex in epithelial prostate cells, we studied the potential utility of assessing PCa progression by measuring citrate levels in PCa tissue. Studies have described the transformation process from benign to malignant epithelial cells and its negative effect on the net citrate production in PCa. 13 Verifying our previous observation, 28 our current measurements indicate correlations between citrate concentrations of 27 prostate tissue samples measured with HRMAS 1 HMRS and the volume percentages of histo-benign epithelial glands from the same tissue samples (Figure 2) , with an interesting new revelation concerning citrate --benign epithelia relationships according to tumor growth rates as represented by PSA velocities. This phenomenon led us to further evaluate the concentrations of citrate in unit histo-benign epithelial glands, where we found statistically significant linear regressions between the increase of PSA velocity and the decrease of measured citrate concentrations (Figure 3) . This relationship was further verified by the correlations between D PSA and FreePSA% with the citrate concentrations as shown in the same figure. As the latter correlations agreed with the current wisdom regarding the relationship between these clinical parameters measured at the time of surgery and PCa development, the former (V PSA ), as a more dynamic parameter, might better reflect the progression process of PCa.
For technical and conceptual reasons, it is not yet possible to observe PCa growth in vivo with human subjects. Therefore, to assess cancer progression, we may either retrospectively analyze PCa cases with and without recurrence, 29 assuming that fastgrowing tumors might be more aggressive and result in metastases after prostatectomy, or, as we did in this study, utilize PCa cases that have shown continuing increases in PSA levels (positive PSA velocities), but with multiple negative biopsies until the final positive biopsies that led to prostatectomy. Although the relationship between PCa growth and the PSA velocity is still under debate, 30 --32 its use as a scientific and clinical marker for PCa progression has been proposed. 33, 34 Our results also emphasize the importance of reliable and accurate measurements of citrate concentration per volume unit of histo-benign epithelial glands. We achieved this by using HRMAS 1 HMRS and quantitative histopathological analysis on the same samples. The HRMAS method applies mechanical rotation of the sample at 54.71 ('magic angle') to the magnetic field. 26 This improves the resolution of the intact tissue spectrum for quantification of individual metabolites, and, at the same time, preserves tissue architecture for histopathological analysis. Without this ability, comparisons of citrate concentrations and the volume percentage of histo-benign epithelia would be impossible.
However, as a 'proof-of-principle' retrospective analysis, there are a number of critical conceptual issues related to this study that can only be addressed by future validations. First of all, because the specimens analyzed in this study were acquired from a PCa tissue bank, while collected under standard Correlations between citrate concentrations and volume percentages of histo-benign epithelia quantified from the same specimens. We grouped the 27 individual measurements into three subgroups according to their PSA velocities (V PSA ). We found the mean (M) and standard deviation (s.d.) of V PSA for the entire group to be 0.00593 and 0.00486 (ng/ml/day), respectively. Using M ± 0.5 s.d., we defined the slow V PSA group to be less than 0.00350 (small dots, n ¼ 12), median V PSA group 0.00350 --0.00836 (median dots, n ¼ 9), and fast V PSA group greater than 0.00836 (large open circles, n ¼ 6) (ng/ml/day). The subgroups of slow and median V PSA groups present much stronger statistically significant linearity (solid line) than that observed for the entire data set (dashed line).
protocol for tissue preservation designed for molecular and genetic analyses, they were not recorded stereotactically in terms of their three-dimensional relationship with tumor foci, including the distance to the nearest focus, in the entire prostate. As previous studies have suggested delocalization of cancerrelated metabolic and molecular parameters to the surroundings of tumor foci, 23 future validation studies should include considerations of metabolic evaluations with respect to their distances from tumor foci through three-dimensional recording sampling sites and reconstruction of PCa 3D maps. Second, with the encouragement of these reported citrate observations, future validations may also include measurement of Zn concentrations in the corresponding histo-benign epithelia to construct a complete picture of Zn-citrate complex relationship with PCa aggressiveness. Such measurements of Zn may be achieved with either histological immunostaining and imaging, 18, 19, 35 or secondary ion mass spectrometry with the assistance of laser capture microdissection.
The results of this study directly address the challenge of differentiating fast from slow-growing PCa detected through annual PSA testing. While these results, low levels of citrate representing rapidly increasing PSA values, and likely fast-growing cancer, rely on measurements conducted on tissue specimens, we cannot eliminate or reduce prostate biopsies. If verified, however, we may predict PCa growth rates by evaluating citrate concentrations in unit benign epithelial glands with tissue samples obtained from the peripheral zone at the time of biopsy. This evaluation can be done either by the HRMAS method followed by histology, or by other biochemical measurements, to indicate the growth rate of PCa and to determine the treatment course for each individual patient. Specifically, such data, in addition to contributing to the knowledge of tumor biology and ultimately to the design of new therapy in general, may contribute to the implementation of alternative treatment options (for example, active surveillance) instead of radical prostatectomy. Avoiding overtreatment will contribute greatly to the prevention of therapeutic side-effects for PCa patients.
